Results from the first U.S. clinical trial investigating the benefit of using a patient's own (autologous) selected adult stem cells, called CD34+ cells, to treat coronary artery disease are promising.
...small-sample, well-designed studies may have sufficient statistical power to produce scientifically valid results, and failure to disprove a null hypothesis may sometimes challenge a well-established body of evidence...raw data must be made available..